Boehringer Ingelheim

Boehringer Ingelheim is a global pharmaceutical company headquartered in Ingelheim am Rhein, Germany. Founded in 1885 by Albert Boehringer, it remains family-owned and is one of the world's largest pharmaceutical firms. The corporation operates in two main business areas: human pharmaceuticals and animal health, with a significant research and development pipeline focused on innovative therapies.

History

The company's origins trace back to 1885 when Albert Boehringer purchased a small tartar factory in Ingelheim am Rhein. A pivotal moment came in 1893 with the industrial production of citric acid using fermentation technology, a process later expanded by chemist Carl Müller. Following World War I, the firm entered the pharmaceutical field, developing alkaloids like papaverine. Under the leadership of Albert Boehringer's son and later Ernst Boehringer, the company expanded internationally, establishing subsidiaries in Tokyo, Milan, and Vienna by the 1960s. Key acquisitions, such as the French company Roussel Uclaf's animal health division in 1997 and parts of Sanofi's animal health business, significantly bolstered its veterinary medicine portfolio.

Business operations

The company is structured into two core business units: Human Pharma and Animal Health. Its global manufacturing network includes major sites in Biberach an der Riss, Ingelheim am Rhein, and Dortmund in Germany, as well as facilities in Saint Joseph, Missouri, and Shanghai. The Animal Health division, operating under the Merial brand name prior to integration, is a global leader, particularly in parasiticides and vaccines. With over 140 affiliated companies, its commercial presence spans the Americas, Europe, and the Asia-Pacific region, employing a workforce of approximately 53,000 people worldwide.

Products and research

The human pharmaceuticals portfolio includes major therapeutic areas such as cardiovascular disease, respiratory diseases, metabolic disorders, and oncology. Notable historic products include Mucosolvan (ambroxol) and Bisvanil (pinaverium bromide). Its current key revenue drivers are drugs like Pradaxa (dabigatran), an oral anticoagulant, and Ofev (nintedanib) for idiopathic pulmonary fibrosis. The company maintains a robust research and development pipeline, with significant investments in biologics and partnerships with biotechnology firms like Ganymed Pharmaceuticals and OSE Immunotherapeutics. The Animal Health division markets leading products such as NexGard and Frontline for parasite control.

Corporate affairs

Ownership and governance remain with the founding families through the Boehringer Ingelheim Foundation and C.H. Boehringer Sohn holding. The company is chaired by Hubertus von Baumbach, a descendant of the founder. It is recognized for its significant investment in R&D, consistently allocating over 20% of net sales to research activities. The corporation engages in numerous public-private partnerships, including collaborations with the Bill & Melinda Gates Foundation on diseases like tuberculosis. Its headquarters in Ingelheim am Rhein features the Boehringer Ingelheim Foundation's funded Institute of Molecular Biology.

Legal and environmental issues

The company has been involved in significant legal proceedings, most notably a 2014 settlement with the U.S. Department of Justice regarding marketing practices for certain drugs. Its anticoagulant Pradaxa was the subject of extensive product liability litigation in the United States, resulting in a major settlement in 2014. On environmental matters, the corporation has committed to ambitious sustainability goals, including achieving carbon neutrality across its operations. It participates in initiatives like the Science Based Targets initiative (SBTi) and has implemented various measures to reduce greenhouse gas emissions and water consumption at its production sites.

Category:Pharmaceutical companies of Germany Category:Companies based in Rhineland-Palatinate Category:Privately held companies of Germany